---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-132883"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:51:09.324643+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics announces positive HAP study results for oral nalbuphine; primary endpoint met at clinical doses

## Summary
- Primary endpoint: mean Emax for 'Drug Liking' for oral nalbuphine 81mg was 71.2 vs IV butorphanol 6mg (82.3), p<0.0001.
- Oral nalbuphine 162mg also statistically significant (74.5 vs 82.3, p=0.0008); 486mg supratherapeutic dose not significant (p=0.3221).
- No serious adverse events reported; secondary endpoints (e.g., 'Take Drug Again,' 'I Feel High') consistent with primary result.
- Results will be included in 8-factor abuse potential analysis for nalbuphine ER as part of planned NDA submission.

## SEC filing metadata
- accession: 0000950170-24-132883
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017024132883/0000950170-24-132883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017024132883/trvi-20241203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-132883
- JSON: https://secwatch.observer/filing/0000950170-24-132883.json
- Plain text: https://secwatch.observer/filing/0000950170-24-132883.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.